We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 109

Court finds no standing for Consumer Watchdog in stem cell patent appeal
  • Shook Hardy & Bacon LLP
  • USA
  • June 12 2014

The Federal Circuit Court of Appeals has rejected not-for-profit Consumer Watchdog's appeal of the U.S. Patent and Trademark Office's (USPTO's


Court denies Myriad’s request to enjoin sale of rival BRCA1BRCA2 tests
  • Shook Hardy & Bacon LLP
  • USA
  • March 20 2014

A federal court in Utah has denied the request for a preliminary injunc- tion filed by Myriad Genetics against a rival company that offered tests


SCOTUS sides with FTC in reverse payment deals
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

A divided U.S. Supreme Court has determined that patent-infringement settlement agreements requiring the patentee to pay the claimed infringer


New infringement lawsuit filed to protect BRCA1 and BRCA2 patents
  • Shook Hardy & Bacon LLP
  • USA
  • June 26 2014

Myriad Genetics has brought a new infringement lawsuit against a company offering a next-generation sequencing test that analyzes the BRCA1 and BRCA2


Federal Circuit’s patent infringement ruling conflicts with USPTO re-examination on validity
  • Shook Hardy & Bacon LLP
  • USA
  • November 1 2012

The Federal Circuit Court of Appeals has denied a request for an en banc rehearing by a medical-device patent holder which argued that the U.S. Patent and Trademark Office’s (USPTO’s) Board of Patent Appeals had effectively nullified a previous Federal Circuit decision on the validity of its patent


Court dismisses action to correct inventorship of two patents
  • Shook Hardy & Bacon LLP
  • USA
  • May 19 2011

A federal court in Massachusetts has determined that genetic researchers could neither substitute themselves as the inventors of two patents nor correct the patents' inventorship to add their names under 35 U.S.C. 256, because they had not engaged in any collaborative efforts with the named inventors


Biosimilars market expected to increase by billions over next four years
  • Shook Hardy & Bacon LLP
  • USA
  • April 7 2011

Market analysts have apparently forecast huge growth in the market for biosimilars due to the upcoming loss of patent exclusivity for a number of branded drugs


FTC reports “pay-for-delay” deal trend continuing
  • Shook Hardy & Bacon LLP
  • USA
  • November 3 2011

The Federal Trade Commission (FTC) has found that the ongoing trend of drug companies settling claims filed by rival generic manufacturers with “pay-for-delay” deals is proceeding unabated


CRS issues overview of IP issues for gene-related discoveries
  • Shook Hardy & Bacon LLP
  • USA
  • August 29 2013

The Congressional Research Service (CRS) recently released a report titled "Gene Patents: A Brief Overview of Intellectual Property Issues." The


Indian pharma interests challenge U.S. allegations of discriminatory treatment
  • Shook Hardy & Bacon LLP
  • India, USA
  • August 29 2013

According to a news source, the Indian Pharmaceutical Alliance (IPA) has challenged U.S. allegations that India's Patent Act discriminates against